Related Experiment Video
Updated: Jun 15, 2026
06:46
Measurement of Tactile Allodynia in a Murine Model of Bacterial Prostatitis
Published on: January 16, 2013
[Efficacy of interleukin-10 for experimental autoimmune prostatitis]
Sen Yang1, Hai-Qi Mu, Lei Zhang
1Department of Urology, The Second Hospital Affiliated to Wenzhou Medical College, Wenzhou, Zhejiang 325027, China.
Zhonghua Nan Ke Xue = National Journal of Andrology
|February 26, 2010
Summary
Interleukin-10 (IL-10) effectively reduces prostate inflammation and lowers levels of tumor necrosis factor-alpha (TNF-alpha) and transforming growth factor-beta1 (TGF-beta1) in experimental autoimmune prostatitis (EAP) rat models.
Area of Science:
- Immunology
- Inflammation Research
- Prostate Biology
Context:
- Experimental autoimmune prostatitis (EAP) is an inflammatory condition of the prostate.
- Cytokines like TNF-alpha and TGF-beta1 play key roles in EAP pathogenesis.
- Interleukin-10 (IL-10) is an immunoregulatory cytokine with potential anti-inflammatory effects.
Purpose:
- To investigate the therapeutic efficacy of IL-10 in a rat model of EAP.
- To assess the impact of IL-10 treatment on prostate inflammation and key cytokine expression.
Summary:
- Wistar rats were induced with EAP and treated with IL-10 or saline.
- Histological analysis (HE staining) and gene expression (RT-PCR) of TNF-alpha and TGF-beta1 were performed.
- IL-10 treatment significantly reduced inflammatory cell infiltration and decreased TNF-alpha and TGF-beta1 levels compared to the EAP group.
Impact:
- IL-10 demonstrates therapeutic potential for autoimmune prostatitis.
- Modulating IL-10 may be a viable strategy for managing prostatitis-related inflammation.
- Findings contribute to understanding cytokine-driven prostatitis and potential treatment targets.
